NCT01160900

Brief Summary

Few reports described outcomes of complete compared with infarct related artery (IRA) only revascularization in patients with ST elevation myocardial infarction (STEMI) and multivessel coronary disease (CAD). The purpose of this study is to determine outcome (death, myocardial infarction, target vessel failure) of 180 consecutive patients with STEMI and multivessel CAD undergoing primary angioplasty. Before the first angioplasty patients are randomized to 2 different strategies: 1) culprit vessel angioplasty only, 2) staged revascularization.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Jul 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2010

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

July 6, 2010

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 13, 2010

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2012

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

July 13, 2010

Status Verified

July 1, 2010

Enrollment Period

1.5 years

First QC Date

July 6, 2010

Last Update Submit

July 12, 2010

Conditions

Keywords

cardiovascular diseasesheart diseasehemorrhagecoronary angioplastydrug eluting stents

Outcome Measures

Primary Outcomes (4)

  • death at 30 days

    1 month

  • stent thrombosis

    1 year

  • target vessel failure

    1 year

  • re-acute myocardial infarction

    1 month

Secondary Outcomes (3)

  • bleeding

    1 month

  • timi frame count

    1 day

  • vascular site access complications

    1 month

Study Arms (1)

multivessel revascularization

EXPERIMENTAL

Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure

Procedure: Coronary angioplasty all lesions

Interventions

treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin

Also known as: drug eluting stent, prasugrel, bivalirudin
multivessel revascularization

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • myocardial acute infarction
  • prolonged chest pain (\>20 minute) started less \<12 hours before arrive in hospital
  • ST segment elevation of \>1mm in \>2 contiguous leads
  • new left bundle branch block
  • diameter of the coronary suitable of angioplasty \>2mm
  • the patients agrees to the study protocol and provides a written consensus
  • two or more coronary suitable for angioplasty

You may not qualify if:

  • refused written consensus
  • hypersensitivity or contraindication to any of the following medications: heparin bivalirudin aspirin prasugrel stainless steel
  • history of bleeding
  • cardiogenic shock (PA \< 90mmHg)
  • chronic total occlusion in the second lesion
  • TIMI Flow \< II in the culprit lesion
  • recent pregnancy
  • history of intra-cerebral major hemorrhagic stroke
  • an elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first six months post enrollment life expectancy \<1 year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Azienda Ospedaliera San Camillo Forlanini

Roma, Italy, 00151, Italy

Location

MeSH Terms

Conditions

Myocardial InfarctionIschemiaHeart FailureNecrosisCardiovascular DiseasesHeart DiseasesHemorrhage

Interventions

Drug-Eluting StentsPrasugrel Hydrochloridebivalirudin

Condition Hierarchy (Ancestors)

Myocardial IschemiaVascular DiseasesInfarctionPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

StentsProstheses and ImplantsEquipment and SuppliesThiophenesSulfur CompoundsOrganic ChemicalsPiperazinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 6, 2010

First Posted

July 13, 2010

Study Start

July 1, 2010

Primary Completion

January 1, 2012

Study Completion

July 1, 2012

Last Updated

July 13, 2010

Record last verified: 2010-07

Locations